Do skeletal-related events predict overall survival in men with metastatic castration-resistant prostate cancer?

被引:47
作者
Howard, L. E. [1 ,2 ]
De Hoedt, A. M. [2 ]
Aronson, W. J. [3 ,4 ]
Kane, C. J. [5 ]
Amling, C. L. [6 ]
Cooperberg, M. R. [7 ]
Terris, M. K. [8 ,9 ]
Divers, C. H. [10 ]
Valderrama, A. [10 ]
Freedland, S. J. [2 ,11 ]
机构
[1] Duke Univ, Sch Med, Dept Biostat & Bioinformat, Durham, NC USA
[2] Vet Affairs Med Ctr, Dept Surg, Div Urol, Durham, NC USA
[3] Univ Calif Los Angeles, Sch Med, Dept Urol, Los Angeles, CA USA
[4] Vet Affairs Greater Los Angeles Healthcare Syst, Dept Surg, Urol Sect, Los Angeles, CA USA
[5] Univ Calif San Diego Hlth Syst, Dept Urol, San Diego, CA USA
[6] Oregon Hlth & Sci Univ, Dept Surg, Div Urol, Portland, OR USA
[7] UCSF Helen Diller Family Comprehens Canc Ctr, Dept Urol, San Francisco, CA USA
[8] Vet Affairs Med Ctr, Dept Surg, Urol Sect, Augusta, GA USA
[9] Med Coll Georgia, Dept Surg, Urol Sect, Augusta, GA 30912 USA
[10] Bayer Pharmaceut, US Hlth Econ, Whippany, NJ USA
[11] Cedars Sinai Med Ctr, Dept Surg, Div Urol, Samuel Oschin Comprehens Canc Inst, 8635 West 3rd St,Suite 1070W, Los Angeles, CA 90048 USA
关键词
BONE METASTASIS; BIOCHEMICAL RECURRENCE; RADICAL PROSTATECTOMY; MORTALITY; MEDICARE; TRIAL; PAIN; ENZALUTAMIDE; PREDNISONE; DOCETAXEL;
D O I
10.1038/pcan.2016.26
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
BACKGROUND: Skeletal-related events (SREs) including pathologic fracture, spinal cord compression, radiation to bone and surgery to bone, are common in men with bone metastatic castration-resistant prostate cancer (mCRPC). Men with mCRPC are at high risk of death. Whether SREs predict mortality is unclear. We tested the association between SREs and overall survival (OS) in a multiethnic cohort with bone mCRPC, controlling for key covariates unavailable in claims data such as bone pain, number of bone metastases and PSA doubling time (PSADT). METHODS: We collected data on 233 men diagnosed with nonmetastatic castration-resistant prostate cancer (CRPC) in 2000-2013 at two Veterans Affairs hospitals who later progressed to bone metastases. First occurrence of SRE and OS were collected from the medical records. Cox models were used to test the association between SRE and OS, treating SRE as a time-dependent variable. We adjusted for age, year, race, treatment center, biopsy Gleason, primary treatment to the prostate, PSA, PSADT, months from androgen deprivation therapy to CRPC, months from CRPC to metastasis and number of bone metastases at initial bone metastasis diagnosis. In a secondary analysis, we also adjusted for bone pain. RESULTS: During follow-up, 88 (38%) patients had an SRE and 198 (85%) died. After adjusting for risk factors, SRE was associated with increased mortality (hazard ratio (HR) = 1.67; 95% confidence interval (CI) 1.22-2.30; P = 0.001). When bone pain was added to the model, the association of SREs and OS was attenuated, but remained significant (HR = 1.42; 95% CI 1.01-1.99; P = 0.042). CONCLUSIONS: SREs are associated with increased mortality in men with bone mCRPC. Further studies on the impact of preventing SREs to increase survival are warranted.
引用
收藏
页码:380 / 384
页数:5
相关论文
共 21 条
[1]   Measurement of skeletal related events in SEER-Medicare: a comparison of claims-based methods [J].
Aly, Abdalla ;
Onukwugha, Eberechukwu ;
Woods, Corinne ;
Mullins, C. Daniel ;
Kwok, Young ;
Qian, Yi ;
Arellano, Jorge ;
Balakumaran, Arun ;
Hussain, Arif .
BMC MEDICAL RESEARCH METHODOLOGY, 2015, 15
[2]  
Beer TM, 2014, NEW ENGL J MED, V371, P424, DOI 10.1056/NEJMoa1405095
[3]   International Variation in Prostate Cancer Incidence and Mortality Rates [J].
Center, Melissa M. ;
Jemal, Ahmedin ;
Lortet-Tieulent, Joannie ;
Ward, Elizabeth ;
Ferlay, Jacques ;
Brawley, Otis ;
Bray, Freddie .
EUROPEAN UROLOGY, 2012, 61 (06) :1079-1092
[4]   Effect of enzalutamide on time to first skeletal-related event, pain, and quality of life in men with castration-resistant prostate cancer: results from the randomised, phase 3 AFFIRM trial [J].
Fizazi, Karim ;
Scher, Howard I. ;
Miller, Kurt ;
Basch, Ethan ;
Sternberg, Cora N. ;
Cella, David ;
Forer, David ;
Hirmand, Mohammad ;
de Bono, Johann S. .
LANCET ONCOLOGY, 2014, 15 (10) :1147-1156
[5]   Denosumab versus zoledronic acid for treatment of bone metastases in men with castration-resistant prostate cancer: a randomised, double-blind study [J].
Fizazi, Karim ;
Carducci, Michael ;
Smith, Matthew ;
Damiao, Ronaldo ;
Brown, Janet ;
Karsh, Lawrence ;
Milecki, Piotr ;
Shore, Neal ;
Rader, Michael ;
Wang, Huei ;
Jiang, Qi ;
Tadros, Sylvia ;
Dansey, Roger ;
Goessl, Carsten .
LANCET, 2011, 377 (9768) :813-822
[6]   Risk of prostate cancer-specific mortality following biochemical recurrence after radical prostatectomy [J].
Freedland, SJ ;
Humphreys, EB ;
Mangold, LA ;
Eisenberger, M ;
Dorey, FJ ;
Walsh, PC ;
Partin, AW .
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 2005, 294 (04) :433-439
[7]   Limitations of prostate specific antigen doubling time following biochemical recurrence after radical prostatectomy: Results from the SEARCH database [J].
Hamilton, Robert J. ;
Aronson, William J. ;
Terris, Martha K. ;
Kane, Christopher J. ;
Presti, Joseph C., Jr. ;
Amling, Christopher L. ;
Freedland, Stephen J. .
JOURNAL OF UROLOGY, 2008, 179 (05) :1785-1789
[8]   Addition of docetaxel, zoledronic acid, or both to first-line long-term hormone therapy in prostate cancer (STAMPEDE): survival results from an adaptive, multiarm, multistage, platform randomised controlled trial [J].
James, Nicholas D. ;
Sydes, Matthew R. ;
Clarke, Noel W. ;
Mason, Malcolm D. ;
Dearnaley, David P. ;
Spears, Melissa R. ;
Ritchie, Alastair W. S. ;
Parker, Christopher C. ;
Russell, J. Martin ;
Attard, Gerhardt ;
de Bono, Johann ;
Cross, William ;
Jones, Rob J. ;
Thalmann, George ;
Amos, Claire ;
Matheson, David ;
Millman, Robin ;
Alzouebi, Mymoona ;
Beesley, Sharon ;
Birtle, Alison J. ;
Brock, Susannah ;
Cathomas, Richard ;
Chakraborti, Prabir ;
Chowdhury, Simon ;
Cook, Audrey ;
Elliott, Tony ;
Gale, Joanna ;
Gibbs, Stephanie ;
Graham, John D. ;
Hetherington, John ;
Hughes, Robert ;
Laing, Robert ;
McKinna, Fiona ;
McLaren, Duncan B. ;
O'Sullivan, Joe M. ;
Parikh, Omi ;
Peedell, Clive ;
Protheroe, Andrew ;
Robinson, Angus J. ;
Srihari, Narayanan ;
Srinivasan, Rajaguru ;
Staffurth, John ;
Sundar, Santhanam ;
Tolan, Shaun ;
Tsang, David ;
Wagstaff, John ;
Parmar, Mahesh K. B. .
LANCET, 2016, 387 (10024) :1163-1177
[9]   Effect of abiraterone acetate and prednisone compared with placebo and prednisone on pain control and skeletal-related events in patients with metastatic castration-resistant prostate cancer: exploratory analysis of data from the COU-AA-301 randomised trial [J].
Logothetis, Christopher J. ;
Basch, Ethan ;
Molina, Arturo ;
Fizazi, Karim ;
North, Scott A. ;
Chi, Kim N. ;
Jones, Robert J. ;
Goodman, Oscar B. ;
Mainwaring, Paul N. ;
Sternberg, Cora N. ;
Efstathiou, Eleni ;
Gagnon, Dennis D. ;
Rothman, Margaret ;
Hao, Yanni ;
Liu, Cameron S. ;
Kheoh, Thian S. ;
Haqq, Christopher M. ;
Scher, Howard I. ;
de Bono, Johann S. .
LANCET ONCOLOGY, 2012, 13 (12) :1210-1217
[10]   The Clinical and Economic Impacts of Skeletal-Related Events Among Medicare Enrollees With Prostate Cancer Metastatic to Bone [J].
McDougall, Jean A. ;
Bansal, Aasthaa ;
Goulart, Bernardo H. L. ;
McCune, Jeannine S. ;
Karnopp, Andy ;
Fedorenko, Catherine ;
Greenlee, Stuart ;
Valderrama, Adriana ;
Sullivan, Sean D. ;
Ramsey, Scott D. .
ONCOLOGIST, 2016, 21 (03) :320-326